Skip to main content

Table 2 Tumor response at 3 months after the combination therapy

From: Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor

Response

Patients, No. (%)

P value

CRAFITY-low (n = 25) *

CRAFITY-intermediate (n = 29) *

CRAFITY-high (n = 16) *

CR

5 (40.00%)

1 (3.45%)

0 (00.00%)

-

PR

12 (48.00%)

13 (44.83%)

4 (25.00%)

-

SD

6 (24.00%)

14 (48.28%)

9 (56.25%)

-

PD

2 (8.00%)

1 (3.45%)

3 (18.75%)

-

ORR

17 (68.00%)

14 (48.28%)

4 (25.00%)

0.026

DCR

23 (92.00%)

28 (96.55%)

13 (81.25%)

0.212

  1. * Data are presented as n (%). CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us